MAPK1IP1L

Across TCGA pan-cancer cohorts, MAPK1IP1L mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MAPK1IP1L’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where MAPK1IP1L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MAPK1IP1L is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

LSCC, LUAD, and HNSC are the cancer types where MAPK1IP1L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAPK1IP1L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	II,III,IV	−0.206	<.001	8	view →
LUAD	Male	All	+0.159	<.001	6	view →
HNSC	Female	All	+0.325	.041	3	view →
PDAC	Male	All	+0.271	.015	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MAPK1IP1L–LSCC

Open the LSCC breakdown →